PACS Group (PACS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.63
- Estimate
- $0.58
- Surprise
- +8.1%
- Revenue (period 2026-09-30)
- $1.50B
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
PACS Group (PACS) beat the $0.58 estimate with adjusted EPS of $0.63 — a clear 8.1% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PACS Sell at 5.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.1% surprise compares with a +25.6% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Thin upside margin: 10.0%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Leverage penalty (D/E 3.1): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $46.68
- Price target
- $51.33
- Stop
- $43.41
- Upside to target
- +10.0%
- Reward-to-risk
- 1.1:1
The stock trades at 27.3× trailing but 17.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
PACS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Care Facilities
- Market cap
- $7.39B
- P/E (fwd)
- 17.1
- P/E (ttm)
- 27.3
- 52-week range
- $10.31–$50.38
- Off 52-week high
- 7.3%
- RSI (14)
- 55
- Volume vs avg
- 0.99×
- Score today
- 5.9/10